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Abstract
Background: Transcription factor 7-like 2 (TCF7L2) has emerged as a consistently replicated susceptibility gene for type 
2 diabetes, however, whether the TCF7L2 gene also has similar effects on the retinal microvasculature is less clear. We 
therefore aimed to investigate the association between the transcription factor 7-like 2 (TCF7L2) rs7903146 
polymorphism and retinal microvascular phenotypes in the Atherosclerosis Risk in Communities (ARIC) Study (1993-
1995).
Methods: This was a population-based, cross-sectional study of 10,320 middle-aged African American (n = 2,199) and 
Caucasian (n = 8,121) men and women selected from four United States communities to examine the association 
between TCF7L2 rs7903146 polymorphism and retinal microvascular signs (retinopathy, focal arteriolar narrowing, 
arteriovenous nicking, arteriolar and venular calibers). Photographs on one randomly selected eye were graded for 
presence of retinal microvascular signs and used to measure retinal vessel calibres.
Results: After adjusting for age, sex, study center, mean arterial blood pressure, total serum cholesterol, triglycerides, 
and other covariates, few associations of TCF7L2 rs7903146 and retinal microvascular signs were noted. TCF7L2 
rs7903146 T risk allele was significantly associated with focal arteriolar narrowing in Caucasians with hypertension 
[odds ratio (OR)CT vs. CC (95% CI) = 1.25 (1.09-1.44); ORTT vs. CC = 1.56 (1.18-2.06); P = 0.002] and in Caucasians without 
diabetes [OR CT vs. CC = 1.18 (1.06-1.32); OR TT vs. CC = 1.40 (1.12, 1.75); P = 0.003]. No significant association of the TCF7L2 
rs7903146 polymorphism and retinal vascular signs was noted among African American individuals.
Conclusions: TCF7L2 rs7903146 is not consistently associated with retinal microvascular signs. However, we report an 
association between the TCF7L2 rs7903146 polymorphism and focal arteriolar narrowing in Caucasians with 
hypertension or without diabetes. Further research in other large, population-based studies is needed to replicate 
these findings.
Background
Retinal microvascular signs (e.g. retinopathy) and
changes in retinal vessel caliber are common fundus find-
ings in adults aged 40 years and older [1]. Narrowing in
retinal vascular caliber has been shown to predict the risk
of diabetes [2] and to be related to retinopathy in people
with diabetes [3], hypertension, or cardiovascular disease
in the general population [1]. In addition to risk factors
such as diabetes and hypertension, genetic factors may
also play a role in the development of these retinal micro-
vascular signs [4,5].
Transcription factor 7-like 2 (TCF7L2), a Wingless and
Int (Wnt) signaling-associated transcription factor
located on chromosome 10q25, has emerged as a consis-
tently replicated susceptibility gene for type 2 diabetes [6-
8], possibly through the impairment of glucagon-like
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Page 2 of 10peptide-1-induced insulin secretion [9]. In our previous
work, we confirmed that the T allele at single nucleotide
polymorphism (SNP) rs7903146 located in intron 3 of
TCF7L2 confers risk for incident type 2 diabetes in mid-
dle-aged African Americans and Caucasians [7]. How-
ever, whether the TCF7L2 gene also has similar effects on
the retinal microvasculature is less clear. To our knowl-
edge, no studies examining the association of the TCF7L2
gene to retinal microvascular signs have been conducted
but two studies evaluated retinopathy, which relies on
less precise global assessments or self-report.
A study in a French population reported no evidence of
an association with prevalent, severe diabetic retinopathy
[10], whereas the InCHIANTI study indicated an associa-
tion of the TCF7L2 gene with reported diabetic retinopa-
thy [11], although the estimates were notably imprecise.
Moreover, potential effects of hypertension on the associ-
ation of TCF7L2 gene and retinopathy have been largely
unexplored.
In this study, we investigated whether the TCF7L2
rs7903146 polymorphism is associated with retinal
microvascular signs and retinal vessel caliber in a large
community-based cohort of African-American and Cau-
casian middle-aged adults. A second objective is to evalu-
ate whether the effect of the rs7903146 SNP varies by
hypertension or diabetes status.
Methods
Study population
The ARIC Study is an ongoing, longitudinal cohort study
of cardiovascular and other major diseases among 15,792
men and women, aged 45 to 64 years old at baseline
(1987-1989), selected from 4 US communities: Forsyth
County, NC; Jackson, MS; the northwestern suburbs of
Minneapolis, MN; and Washington County, MD [12]. By
design, African-Americans were over-sampled at the For-
syth County site and were exclusively sampled in Jackson
and thus constituted 27% of the baseline cohort. Of the
15,792 participants at baseline, 12,887 (86%) returned for
the third examination when retinal photography was first
performed in 1993-1995.
We excluded ARIC participants who were not African-
American or Caucasian (n = 38), African-Americans
from Minnesota and Maryland field centers (n = 42), par-
ticipants with missing genotype data or who did not pro-
vide consent for the use of their DNA (n = 803),
participants who did not have retinal photographs (n =
224), participants who had ungradeable photographs (n =
1458), and participants who had diabetes diagnosed
before 20 years old (n = 2). After these exclusions, 10,320
participants (2,199 African American and 8,121 Cauca-
sians) were available for analysis. Characteristics of par-
ticipants with and without gradable retinal photographs
have been previously described [13,14]. The institutional
review boards at all participating institutions and at the
Fundus Photograph Reading Center at the University of
Wisconsin approved the procedures and all participants
included in the analysis gave informed consent.
Assessment of Retinal Microvascular Signs
The retinal photography procedures and grading of reti-
nal microvascular signs have been published in detail
elsewhere [13]. In brief, one eye was randomly selected
from each participant and a 45° retinal photograph, cen-
tered on the region of the optic disc and the macula, was
taken using an autofocus film camera after a five-minute
dark adaptation. If the selected eye was considered too
difficult or not possible to photograph with adequate
quality, the other eye was photographed instead.
These retinal photographs were evaluated at the Fun-
dus Photograph Reading Center at the University of Wis-
consin, Madison, by trained graders who were masked to
participant characteristics. We measured and defined the
presence of focal retinal microvascular abnormalities,
including retinopathy, arteriovenous (AV) nicking, and
focal arteriolar narrowing. Retinopathy was defined
based on the presence of any of the following lesions: ret-
inal hemorrhages (blot or flame shaped), microaneu-
rysms, soft or hard exudates, macular edema, intraretinal
microvascular abnormalities, venous beading, swelling,
or laser photocoagulation scars. AV nicking and focal
arteriolar narrowing were defined as present if graded as
definite or probable and as absent if not. Retinal arteriolar
and venular calibers were measured using a computer-
assisted approach. The fundus photographs were digi-
tized and the diameters of all arterioles and venules in an
area half to one disc diameters from the optic disc were
measured. These diameters were summarized as the cen-
tral retinal artery equivalent (CRAE) and the central reti-
nal venular equivalent (CRVE) [13]. Quality control
procedures have been previously reported [13].
TCF7L2 Genotyping
The TCF7L2 rs7903146 SNP was genotyped by the ARIC
Central Laboratory using Taqman® assays (Applied Bio-
systems, Foster City, CA). Laboratory-designed probes
were obtained from Applied Bioystems and primers from
IDT (Coralville, IA). All PCR reactions took place in opti-
cal 384-well reaction plates (Applied Biosystems). Five
percent of samples were re-genotyped for quality control
as blind duplicates. The percent agreement between
blind duplicates was 98% and the simple Kappa coeffi-
cient was 0.97 indicating good genotyping quality.
Measurement of Covariates
Self-reported race, sex, and study center were ascertained
at baseline (1987-1989). Other covariates including age,
current smoking, obesity, total serum cholesterol, total
Yan et al. BMC Endocrine Disorders 2010, 10:9
http://www.biomedcentral.com/1472-6823/10/9
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antihypertensive medication were obtained at visit 3
(1993-1995). At each visit, blood pressure was measured
three times using a random zero sphygmomanometer
and the average of the last two measurements was used
for analyses. Hypertension was defined as systolic blood
pressure ≥140 mmHg or diastolic blood pressure ≥90
mmHg or current use of anti-hypertension medication
use at visit 1, 2, or 3 [15]. Mean arterial blood pressure
was defined as one-third of systolic blood pressure plus
two-thirds of diastolic blood pressure at visit 3 [16]. Dia-
betes was defined as fasting serum glucose levels of at
least 7.0 mmol/L (126 mg/dl), nonfasting glucose levels of
at least 11.1 mmol/L (200 mg/dl), current use of hyperg-
lycemic medications, or a self-reported physician diagno-
sis of diabetes at visit 1, 2 or 3 [17]. Plasma total
cholesterol and triglyceride levels were measured by
enzymatic methods; high-density lipoprotein cholesterol
(HDL-C) was measured after dextran-magnesium precip-
itation of the non-HDL-C; and glucose was assessed by a
modified hexokinase/glucose-6-phosphate dehydroge-
nase procedure [18]. Self-reported cigarette smoking
exposure was defined as current smoking versus non-
smoking obtained by a personal interview. Body mass
index (BMI) was calculated as measured weight (kg)
divided by the square of measured height (m2). Individu-
als with a BMI ≥30 kg/m2 were classified as obese [19].
Statistical Analysis
All analyses were stratified by race to crudely account for
population stratification. To assess whether genotype dis-
tribution within each race departed from Hardy-Wein-
berg equilibrium, a χ2 goodness-of-fit test was used.
Logistic regression was used to model the association of
focal retinal lesions (retinopathy, focal arteriolar narrow-
ing, AV nicking) with the TCF7L2 rs7903146 polymor-
phism, and odds ratios (ORs) and 95% confidence
intervals (CIs) were obtained. Following published litera-
ture [8] and our previous findings [7], we assumed an
additive mode of inheritance and compared heterozygous
CT-genotype and homozygous TT-genotype individuals
to CC-genotype individuals, using the rs7903146 CC-
genotype as the referent group. A variable taking on the
values 0 for genotype CC, 1 for genotype CT, and 2 for
genotype TT was used to test for log additive genetic
effects in logistic regression models. Generalized linear
models were used to obtain adjusted mean retinal vascu-
lar calibers (CRAE, CRVE) for each genotype of
rs7903146. All models were adjusted for age, study center,
sex, current smoking (yes/no), obesity (yes/no), total
serum cholesterol, total serum triglycerides, mean arte-
rial blood pressure, and antihypertensive medication.
Hypertension was also included in the model when it was
not assessed as an effect measure modifier.
As hypertension and diabetes are strongly associated
with retinal microvascular signs and TCF7L2 is a diabe-
tes-related gene, we assessed the potential interactions
between genotype and hypertension, and interactions
between genotype and diabetes on retinal microvascular
phenotypes, respectively, and performed sub-group anal-
yses with and without hypertension/diabetes. With
regard to multiplicative interaction, variables were con-
sidered to be potential effect measure modifiers if they
departed from multiplicativity assessed by the Wald χ2
test for significance of the estimated β-coefficient for the
interaction term [20]. For additive interaction, variables
were considered as potential modifiers if departure from
additivity was detected by the interaction contrast ratio
(ICR) [20,21]. ICRs were quantified as follows: ICR =
OR_AB - OR_A - OR_B + 1, where OR_AB represents
the joint effect of hypertension/diabetes and the SNP, and
OR_A and OR_B represent the main effects of hyperten-
sion/diabetes and the SNP, respectively [20]. Thus, ICR
refers to the increased odds due to an additive interaction
between hypertension/diabetes and the T risk allele
adjusted for aforementioned covariates. Assuming an
additive mode of inheritance, the ICR comparing TT to
CT is equal to the ICR comparing CT to CC, thus only
one ICR was reported. Departures from zero suggest that
hypertension/diabetes and the SNP interact to cause reti-
nal microvascular signs. The OR and the variance covari-
ance matrix were used to calculate ICR values and P
values [21]. For retinal vascular calibers (CRAE, CRVE),
only the P value from multiplicative interaction test was
estimated. A p value <0.05 was considered to indicate an
important modifier for both multiplicative and additive
interaction assessments, despite the multiple tests as
interaction tests tend to be underpowered [22].
Results
The rs7903146 T allele was observed with same fre-
quency (29%) in African-American and Caucasian indi-
viduals, and the genotype frequencies for rs7903146 in
both races were consistent with Hardy-Weinberg equilib-
rium (P > 0.05). Selected characteristics of the ARIC
Study participants by race and genotype status are pre-
sented in Table 1. No statistically significant differences
in demographic or behavioral characteristics (sex, and
current smoking) were noted by genotype status except
for age (P = 0.03) and HDL-C levels (P = 0.05) in Cauca-
sian participants (Table 1). Moreover, no statistically sig-
nificant differences in hypertension, mean arterial blood
pressure, obesity, triglycerides, LDL-C, and total choles-
terol by genotype were noted except for individuals with
T allele who had significantly higher fasting glucose and
were more likely to be diabetic in Caucasians (Table 1).
The associations between retinal lesions and rs7903146
are presented in Table 2. The heterozygous CT-genotype
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higher prevalence of retinal lesions when compared with
CC-genotype individuals in both races except for AV
nicking in Caucasians. Assuming an additive mode of
inheritance, the rs7903146 T allele was marginally signifi-
cantly associated with prevalent focal arteriolar narrow-
ing in Caucasians [ORCT vs. CC (95% CIs) = 1.11 (1.00,
1.23); ORTT vs. CC (95% CIs) = 1.23 (1.00, 1.51); P = 0.05],
but not in African American participants [ORCT vs. CC
(95% CIs) = 1.10 (0.88, 1.36); ORTT vs. CC (95% CIs) = 1.20
(0.78, 1.85); P = 0.40] (Table 2). No significant associa-
tions were noted for AV nicking, retinopathy, or retinal
arteriolar or venular diameters (CRAE, CRVE) with
rs7903146 (Table 3).
Hypertension and diabetes were important effect mea-
sure modifiers for focal arteriolar narrowing in Cauca-
sians [multiplicative P = 0.03 (hypertension), P = 0.04
(diabetes); additive ICR = 0.41 and P = 0.006 (hyperten-
sion), ICR = -0.29 and P = 0.04 (diabetes)], but not in
African American participants (P > 0.05). When stratified
Table 1: Distribution of selected characteristics by race and rs7903146 genotype status
African American Caucasian
CC CT TT P valuea CC CT TT P valuea
n 1099 923 177 4105 3321 695
Age, years 58.4 ± 5.6 58.3 ± 5.4 58.9 ± 5.6 0.36 60.1 ± 5.6 59.9 ± 5.6 59.6 ± 5.6 0.03
Male sex 399 (36.31) 353 (38.24) 65 (36.72) 0.66 1894 (46.14) 1528 (46.01) 339 (48.78) 0.39
Current smoker 232 (21.28) 194 (21.20) 34 (19.32) 0.86 672 (16.38) 570 (17.17) 117 (16.83) 0.66
Obesity Presentb 516 (46.95) 418 (45.29) 86 (48.86) 0.60 1223 (29.81) 926 (27.92) 200 (28.78) 0.20
Hypertension 
Presentc
720 (65.51) 619 (67.06) 116 (65.54) 0.75 1612 (39.28) 1311 (39.48) 262 (37.70) 0.68
Arterial blood 
pressure, mm Hgd
94.06 ± 12.87 94.28 ± 12.61 92.98 ± 12.76 0.46 87.83 ± 11.08 87.55 ± 11.38 87.24 ± 11.05 0.32
Diabetes Presente 283 (25.75) 258 (27.95) 58 (32.77) 0.12 534 (13.01) 536 (16.14) 136 (19.57) <0.0000
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Data are means ± SD or n (%) unless otherwise indicated. Abbreviations: HDL-C, high density lipoprotein cholesterol; LDL-C, low density 
lipoprotein cholesterol. aP value is based on ANOVA (continuous) and χ2 (categorical), comparing differences for individual characteristic across 
genotypes; bobesity was defined as body mass index ≥30 kg/m2; chypertension was defined as systolic blood pressure ≥140 mmHg or diastolic 
blood pressure ≥90 mmHg or a history of anti-hypertension medication use; dmean arterial blood pressure was defined as one-third of systolic 
blood pressure plus two-thirds of diastolic blood pressure; ediabetes was defined as fasting serum glucose levels of at least 7.0 mmol/L (126 mg/

























































n No. with 
Lesion (%)
OR (95% CI)a P valueb n No. with 
Lesion (%)
OR (95% CI)a P valueb
AV nicking CC 1083 179 (16.53) 1.00 0.24 4058 585 (14.42) 1.00 0.58
CT 915 156 (17.05) 1.12 (0.93, 1.35) 3286 433 (13.18) 1.03 (0.93, 1.14)




CC 1076 136 (12.64) 1.00 0.40 4041 598 (14.80) 1.00 0.05
CT 912 120 (13.16) 1.10 (0.88, 1.36) 3268 543 (16.62) 1.11 (1.00, 1.23)
TT 173 26 (15.03) 1.20 (0.78, 1.85) 688 104 (15.12) 1.23 (1.00, 1.51)
Retinopathy CC 1099 138 (12.56) 1.00 0.36 4105 236 (5.75) 1.00 0.27
CT 923 128 (13.87) 1.10 (0.90, 1.35) 3321 205 (6.17) 1.09 (0.94, 1.26)
TT 177 24 (13.56) 1.21 (0.81, 1.81) 695 45 (6.47) 1.18 (0.88, 1.58)
Abbreviations: AV, arteriovenous; CI, confidence interval; OR, odds ratio. aAdjusted for age, study center, gender, current smoking (yes/no), obesity, total serum cholesterol, total serum 




















































Table 3: Mean retinal vessel calibers (CRAE/CRVE) by TCF7L2 rs7903146 genotype, by race
African American Caucasian
Retinal Vessel Index Geno-type n Multivariate 
Adjusteda
P valueb n Multivariate 
Adjusteda
P valueb
Mean retinal arteriolar 
diameter (95% CI), μm
CC 1090 161.61 (160.07, 163.15) 0.49 4096 163.25 (162.42, 164.08) 0.24
CT 916 161.94 (160.40, 163.48) 3312 162.97 (162.16, 163.79)
TT 177 162.27 (160.24, 164.29) 694 162.69 (161.65, 163.73)
Mean retinal venular 
diameter (95% CI), μm
CC 1090 200.36 (198.79, 201.94) 0.32 4096 197.52 (196.69, 198.35) 0.94
CT 916 199.86 (198.28, 201.45) 3312 197.54 (196.72, 198.36)
TT 177 199.36 (197.25, 201.47) 694 197.56 (196.51, 198.60)
Abbreviations: CI, confidence interval; CRAE, central retinal artery equivalent; CRVE, central retinal venular equivalent.
aAdjusted for age, study center, gender, current smoking (yes/no), obesity, total serum cholesterol, total serum triglycerides, mean arterial blood pressure, hypertension, antihypertensive 
medication, and CRAE (when the outcome is CRVE)/CRVE (when the outcome is CRAE); bP value for 1 degree freedom test of association between vessel calibers and rs7903146 under the log 
additive genetic model.
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was significantly associated with an increased odds of
focal arteriolar narrowing in Caucasian individuals, how-
ever only among those with hypertension or without dia-
betes (Table 4); no associations were noted in African
American participants (data not shown). Our analysis in
Caucasian individuals with hypertension AND without
diabetes indicated that TCF7L2 rs7903146 was associated
with focal arteriolar narrowing [ORCT vs. CC (95% CIs) =
1.40 (1.19, 1.64); ORTT vs. CC (95% CIs) = 1.96 (1.43, 2.68);
P < 0.0001], which is consistent with our interaction anal-
yses. No significant interactions with hypertension or
diabetes were observed for other retinal lesions and reti-
nal vessel calibers (CRAE, CRVE).
Discussion
Our study reports on the association between the
TCF7L2 rs7903146 polymorphism and retinal microvas-
cular lesions and retinal vascular caliber in a middle-aged
African-American and Caucasian population. No associ-
ations were noted except for focal arteriolar narrowing in
Caucasians. The TCF7L2 rs7903146 was significantly
associated with a greater frequency of focal arteriolar
narrowing among Caucasians with hypertension or with-
out diabetes, but not among those without hypertension
or with diabetes, suggesting an interaction between
TCF7L2 variants and hypertension and diabetes status in
Caucasians.
To our knowledge, there are few studies for direct com-
parison. An earlier case-control study in a French popula-
tion reported the lack of an association with severe
retinopathy (effect estimates not reported) [10], which is
consistent with our findings on retinopathy in Cauca-
sians. The InCHIANTI study of elderly Europeans
reported an association with diabetic retinopathy in 127
persons with diabetes. However the number of partici-
pants with diabetic retinopathy was very small (n = 12)
and results were not statistically significant [11]. Notably,
these two studies did not report the definition for retin-
opathy used, which may differ from ours.
We observed an association between TCF7L2
rs7903146 and focal arteriolar narrowing in Caucasians,
but not in African Americans. The lack of association in
the African American examinees could reflect confound-
ing by unmeasured covariates that are differentially dis-
tributed in African American and Caucasian participants,
which warrants further investigation. More likely how-
ever, the limited power to detect such a modest effect in
the African American sample (calculated as 26% for a rel-
ative risk of 1.15) may explain our findings (Additional
file 1, Figure S1). The latter is supported by the observa-
tion of very similar effect size estimates between African
American and Caucasian participants, and therefore war-
rants further study in additional African American popu-
lations.
It is not known why TCF7L2 rs7903146 was associated
with retinal focal arteriolar narrowing. To determine
whether the effect of TCF7L2 rs7903146 on focal arterio-
lar narrowing was due to hyperglycemia, we further
adjusted for fasting glucose values in the models, but no
attenuation of genetic effects were noted. It is possible
that the TCF7L2 rs7903146 variant may be related to
focal arteriolar narrowing not through its effect on diabe-
tes but through other, retinal-specific mechanisms (i.e.
pleiotropic effects). The Wnt/β-catenin/T-cell factor
(TCF) (canonical) signaling pathway may inhibit the adi-
pogenic differentiation of pericytes (a contractile cell in
small retinal arterioles), which may have a later effect in
regulating retinal microvascular function. This pathway
also regulates vascular smooth muscle cell proliferation,
suggesting that it may be involved in intimal thickening
[23]. Prolonged exposure to elevated blood pressure may
lead to retinal vessel vasospasm, intimal thickening,
medial hyperplasia and arteriosclerosis manifesting as
either generalized or focal arteriolar narrowing [24].
However, we found only a relation with focal and not gen-
eralized arteriolar narrowing as measured by CRAE and
biological mechanisms remain speculative.
An alternate explanation of our positive findings could
be chance considering the large number of comparisons
made in assessing association in the context of possible
effect modification. To minimize the impact of the multi-
ple tests we could apply a crude Bonferroni correction
(five phenotypes in the context of multiple strata defined
by diabetes, hypertension, combined diabetes and hyper-
tension grouping, and the full sample N = 30), noting that
such an approach is an over-correction because many of
the analytic runs assessed the same dependent variable. If
such a correction were applied, most of the results
reported in this paper would not be statistically signifi-
cant except in the subgroup with hypertension AND
without diabetes.
Our study has notable strengths, including a large, pop-
ulation-based cohort, standardized assessment of retinal
photographs, and detailed information on a variety of risk
factors. To our knowledge, this is the first population-
based study that systematically examines the association
between TCF7L2 rs7903146 and retinal microvascular
lesions and caliber in middle-aged African Americans
and Caucasians.
Several important limitations also deserve mention.
First, grading was performed from a single 45° fundus
photograph that was taken through a nonpharmacologi-
cally dilated pupil. This can underestimate the prevalence
of retinal microvascular lesions, which could have biased
the results toward the null. Second, we found that the




















































Table 4: Retinal Lesions and TCF7L2 rs7903146 genotype by hypertension or diabetes status in Caucasians
With Hypertension Without Hypertension With Diabetes Without Diabetes
Retinal 
Lesion
n No. with 
Lesion (%)
OR (95% CI)a n No. with 
Lesion (%)
OR (95% CI)a n No. with 
Lesion (%)
OR (95% CI)a n No. with 
Lesion (%)
OR (95% CI)a
AV nicking CC 1595 280 (17.55) 1.00 2462 305 (12.39) 1.00 525 89 (16.95) 1.00 3533 496 (14.04) 1.00
CT 1297 222 (17.12) 1.18 (1.02, 1.36) 1989 211 (10.61) 0.91 (0.78, 1.05) 525 88 (16.76) 0.99 (0.78, 1.26) 2761 345 (12.50) 1.04 (0.92, 1.16)
TT 259 60 (23.17) 1.39 (1.04, 1.86) 430 46 (10.70) 0.83 (0.61, 1.11) 134 21 (15.67) 0.98 (0.61, 1.58) 555 85 (15.32) 1.07 (0.85, 1.35)




CC 1584 330 (20.83) 1.00 2456 268 (10.91) 1.00 519 88 (16.96) 1.00 3522 510 (14.48) 1.00
CT 1290 320 (24.81) 1.25 (1.09, 1.44) 1978 223 (11.27) 0.96 (0.82, 1.12) 526 91 (17.30) 0.85 (0.65, 1.11) 2742 452 (16.48) 1.18 (1.06, 1.32)
TT 259 67 (25.87) 1.56 (1.18, 2.06) 429 37 (8.62) 0.92 (0.68, 1.25) 136 15 (11.03) 0.73 (0.42, 1.24) 552 89 (16.12) 1.40 (1.12, 1.75)
P valueb 0.002 0.59 0.24 0.003
Retinopathy CC 1612 136 (8.44) 1.00 2492 100 (4.01) 1.00 534 78 (14.61) 1.00 3571 158 (4.42) 1.00
CT 1311 112 (8.54) 1.04 (0.85, 1.26) 2010 93 (4.63) 1.12 (0.90, 1.39) 536 76 (14.18) 1.05 (0.82, 1.34) 2785 129 (4.63) 1.01 (0.84, 1.22)
TT 262 23 (8.78) 1.08 (0.73, 1.60) 433 22 (5.08) 1.26 (0.81, 1.94) 136 23 (16.91) 1.10 (0.67, 1.8) 559 22 (3.94) 1.02 (0.70, 1.48)
P valueb 0.71 0.31 0.71 0.91
Abbreviations: AV, arteriovenous; CI, confidence interval; OR, odds ratio.
aAdjusted for age, study center, gender, current smoking (yes/no), obesity, total serum cholesterol, total serum triglycerides, mean arterial blood pressure, hypertension (when stratified by 
diabetes), and antihypertensive medication; bP value for OR in the log additive genetic model.
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0.03). This association could have arisen by chance; the
pathophysiology underlying any relationship between AV
nicking and rs7903146 has not been established. Third, as
diabetes and fasting glucose values are plausibly interme-
diate variables between TCF7L2 and retinal phenotypes,
our analyses conditional on diabetes/fasting glucose val-
ues need to be interpreted with caution as this method
may introduce confounding [25]. Fourth, as polymor-
phisms within TCF7L2 possibly impair the glucagon like
peptide-1 induced insulin secretion [9], which in turn
could lead to a lower postprandial insulin secretion, we
might expect to see a stronger effect among patients with
impaired glucose tolerance. However, the oral glucose
tolerance test was not performed at visit 3 when the fun-
dus photographs were taken. Finally, our samples of Afri-
can American and diabetic Caucasians are limited to
2,199 and 1,206 examinees, respectively, thus true associ-
ations between retinal lesions and the TCF7L2 variant
could have been missed in these subpopulations. Replica-
tion of our findings in other large, population-based stud-
ies could help better elucidate these relationships.
Conclusions
In summary, TCF7L2 rs7903146 is not consistently asso-
ciated with retinal microvascular signs. However, our
study is the first to report an association between the
TCF7L2 rs7903146 polymorphism and focal arteriolar
narrowing in Caucasians with hypertension or without
diabetes. No significant associations were noted for other
retinal microvascular signs in either race group. Other
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